MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/500/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/500/0.01/20.09.24 Share Price

DE000ME58FJ0

Real-time Bid/Ask 08:22:00 04/07/2024 pm IST
0.136 ^EUR / 0.154 ^EUR	+7.41%

Current month	-15.09%
1 month	-22.86%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/500/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	02/07	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	02/07	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	CI

More news

Quotes 5-day view

Date	Price	Change
04/24/04	0.138	+2.22%
03/24/03	0.135	-11.18%
02/24/02	0.152	+5.56%
01/24/01	0.144	-9.43%
28/24/28	0.159	+2.58%

Delayed Quote Börse Stuttgart

Last update July 04, 2024 at 07:07 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME58FJ
ISIN	DE000ME58FJ0
Date issued	13/12/2023
Strike	500 $
Maturity	20/09/2024 (78 Days)
Parity	100 : 1
Emission price	0.1 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	0.25 €
Lowest since issue	0.059 €
Delta	0.38x
Omega	11.39
Premium	9.67x
Gearing	29.82x
Moneyness	0.9406
Difference Strike	29.72 $
Difference Strike %	+5.94%
Spread	0.018 €
Spread %	11.61%
Theoretical value	0.1440
Implied Volatility	29.08 %
Total Loss Probability	66.96 %
Intrinsic value	0.000000
Present value	0.1440
Break even	515.56 €
Theta	-0.01x
Vega	0.01x
Rho	0x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

470.3 USD

Average target price

468.3 USD

Spread / Average Target

-0.43%

Consensus